Reliability and Validity of Selected PROMIS Measures in People with Rheumatoid Arthritis

Susan J. Bartlett1,2*, Ana-Maria Orbai2, Trisha Duncan2, Elaine DeLeon2, Victoria Ruffing2, Katherine Clegg-Smith3, Clifton O. Bingham, III2

1 Department of Medicine, Divisions of Clinical Epidemiology, Rheumatology, and Respiratory Epidemiology, McGill University / McGill University Health Centers, Montreal, QC, Canada, 2 Department of Medicine, Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, United States of America, 3 Bloomberg School of Public Health, Center for Qualitative Studies in Health and Medicine, Johns Hopkins University, Baltimore, MD, United States of America

* susan.bartlett@mcgill.ca

Abstract

Purpose

To evaluate the reliability and validity of 11 PROMIS measures to assess symptoms and impacts identified as important by people with rheumatoid arthritis (RA).

Methods

Consecutive patients (N = 177) in an observational study completed PROMIS computer adapted tests (CATs) and a short form (SF) assessing pain, fatigue, physical function, mood, sleep, and participation. We assessed test-test reliability and internal consistency using correlation and Cronbach’s alpha. We assessed convergent validity by examining Pearson correlations between PROMIS measures and existing measures of similar domains and known groups validity by comparing scores across disease activity levels using ANOVA.

Results

Participants were mostly female (82%) and white (83%) with mean (SD) age of 56 (13) years; 24% had ≤ high school, 29% had RA ≤ 5 years with 13% ≤ 2 years, and 22% were disabled. PROMIS Physical Function, Pain Interference and Fatigue instruments correlated moderately to strongly (rho’s ≥ 0.68) with corresponding PROs. Test-retest reliability ranged from .725–.883, and Cronbach’s alpha from .906–.991. A dose-response relationship with disease activity was evident in Physical Function with similar trends in other scales except Anger.

Conclusions

These data provide preliminary evidence of reliability and construct validity of PROMIS CATs to assess RA symptoms and impacts, and feasibility of use in clinical care. PROMIS instruments captured the experiences of RA patients across the broad continuum of RA.
symptoms and function, especially at low disease activity levels. Future research is needed to evaluate performance in relevant subgroups, assess responsiveness and identify clinically meaningful changes.

Introduction

There is growing recognition of the importance of placing patients at the center of healthcare by developing patient-centered care models and integrating patient-valued outcomes into shared decision-making [1, 2]. Patient-reported outcomes (PROs) contribute essential information from the perspective of people living with a chronic disease and its treatments about the status of or a change in their physical, emotional, and social health outcomes [3].

Arthritis is the leading cause of disability in the US [4]. Rheumatoid arthritis (RA), the most common form of inflammatory arthritis, is a painful, disabling, and destructive disease that greatly impairs quality of life and shortens the lifespan [5–7]. RA cannot be cured and everyday life with RA is strongly influenced by symptoms that fluctuate widely and have far-reaching impacts on physical, mental, and social health [8, 9]. In RA, three PROs have been included within the American College of Rheumatology core set of outcome measures recommended for use in randomized clinical trials (RCTs) [10] and clinical care [11] including global ratings of disease activity or health, pain, and physical function; more recently, fatigue also has been recommended for inclusion [10, 12, 13]. However, other symptoms and impacts of importance to RA patients include stiffness, sleep disturbance, emotional distress, and participation in life activities [14–18]. Also, with the goal of RA treatment now remission or low disease activity (LDA), it is important to be able to monitor subtle improvements and worsening of symptoms and function [18–20].

The process for developing and validating PROs has evolved considerably over the last two decades and now includes recommendations to identify patient-relevant symptoms and impacts through rigorous qualitative and psychometric processes and demonstrate validity in the targeted patient population and context of intended use (e.g. RCT vs. clinical practice) [21–23]. As instruments from RCTs are adopted for use in “real world” settings and pragmatic clinical trials, limitations such as floor and ceiling effects of some “gold-standard” instruments become an important concern [24–26]. The lack of a common metric across instruments hampers interpretation and comparisons across studies. PROs used in clinical practice to inform medical decision-making may require higher levels of precision and responsiveness than is found in those developed for research purposes in order to reflect changes at the individual level. Thus, ideal PROs for use in RA clinical care: a) reflect the aspects of health relevant to people living with the disease [14–16, 27]; b) accurately and precisely measure the symptom or impact across the continuum of disease activity; c) are minimally burdensome to patients and clinicians; d) produce a simple score on a common metric; and e) can be easily interpreted in absolute terms (“the state” or severity of the symptom) or as a change in terms of improvement and worsening.

The Patient Reported Outcome Measurement Information System (PROMIS®) was developed by the National Institutes of Health (NIH) to provide a standardized metric for measuring physical, mental, and social health across chronic diseases (www.nihpromis.org). PROMIS instruments are publicly available, were developed using item response theory, and have been tested in more than 20,000 individuals drawn from the general US population [28, 29]. Both short forms (SF) and computerized-adaptive tests (CATs) are available to assess common
symptoms and function. Results are reported using a common metric (i.e., a T-score with a mean of 50 and standard deviation (SD) of 10) and have been normed to the US population. To date, only the PROMIS Physical Function scale has been evaluated in RA [24, 25].

In earlier work, we identified domains that people with RA considered impactful on their health-related quality of life (HRQL) [15, 18]. Here, we describe the performance and validation of 11 PROMIS instruments in adults with RA in the context of ongoing care. We hypothesized that as compared with the general US population, PROMIS scores in people with RA would reflect greater HRQL impairments related to pain, fatigue, sleep, mood, physical function, and participation. We also hypothesized that scores would correlate moderately to strongly with existing legacy instruments assessing similar constructs and would show evidence of a dose-response relationship with disease activity levels.

Materials and Methods

Data are from a prospective cohort study of people receiving guideline-based RA care in an academic rheumatology clinic. All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Johns Hopkins Institutional Review Board (NA00071923). After providing written informed consent, coordinators registered participants in Assessment Center (www.assessmentcenter.net), a secure online PROMIS research management tool.

Sample

Adults ages 18+ who were fluent in English and were enrolled in our clinical practice registries were eligible to participate. Exclusions were significant medical or psychiatric illness that the treating clinician felt would limit an individual’s ability to participate in the study.

Procedures

Individuals were consecutively approached by phone or at the time of a routine clinic visit and provided with details about the study. After providing written informed consent, coordinators registered participants in Assessment Center (www.assessmentcenter.net), a secure online PROMIS research management tool. Assessment Center provides access to the CATs, SFs and study-specific questionnaires, and will automatically generate a report containing scores for PROMIS CATs. After checking in with the clinic receptionist, participants were given a tablet computer linked to a study-specific URL to complete questionnaires described below. RA legacy instruments were also completed. A subset of participants were consecutively approached and asked to complete the same PROMIS measures 2 days later to assess test-retest reliability.

Measures

**Sociodemographic and RA Characteristics.** Socio-demographic information was drawn from the patient’s medical record and included age, sex, race/ethnicity, education, work status, RA duration, and RF/CCP status. Swollen and tender joint counts (28 joints) and MD global assessments of disease activity (100 mm VAS) were provided by treating rheumatologists. Clinical disease activity index scores (CDAI) were calculated to assess disease activity level.

**Patient Reported Outcomes.** Legacy RA PROs that are routinely collected included the Patient Global Assessment (100 mm VAS), Pain (100 mm VAS), the 8-item Modified Health Assessment Questionnaire of disability (M-HAQ, 0–3 scale), [10] and a fatigue 100 mm VAS [30]; with each measure, higher scores reflect more of the symptom. PROMIS instruments for
physical, emotional, and social domains were selected based on earlier work [14–17]. Version 1.0 CATs were administered for: Pain Interference, Fatigue, Sleep Disturbance, Sleep-Related Impairment, Depression, Anxiety, Anger, and Physical Function; the 3-item PROMIS Pain intensity SF was also included. Version 2.0 CATs were administered for Ability to Participate in Social Roles and Satisfaction with Social Roles and Activities. Specific items, response options, and anchors are available through www.assessmentcenter.net. Scales were administered in fixed order, and CATs were programmed to administer from 4–8 items until a standard error (precision of estimate) fell at or below 0.3. Higher scores indicate more of the trait being measured, so that for physical function, participation, and satisfaction, a higher score is “better”, whereas for symptoms, higher scores indicate higher levels of the symptom.

Statistical Analysis

Pearson coefficients and Spearman’s rho were used to examine the degree to which PROMIS scores were consistent with each other and legacy PROs for similar domains. ANOVA was used to compare domain scores for PROMIS and legacy variables by CDAI disease activity levels. Pearson correlation and Cronbach’s alpha were used to assess reproducibility and internal consistency; reliability >.7 was considered acceptable. Analyses were done using IBM SPSS version 22.

Results

Patient Characteristics

A total of 177 patients were enrolled and completed the surveys between September 2012 and November 2013. The sample reflected a diverse spectrum of sociodemographic and RA characteristics (Table 1). Participants were mostly female (82%) and white (83%) with mean (SD) age of 56 (13) years. Most (92%; 162/177) met ACR2010 criteria for RA [31]. Nearly a quarter (24%) had a high school education or less, and 22% reported being disabled due to RA. Disease duration ranged from 0–41 years; 29% had RA ≤ 5 years with 13% ≤ 2 years. Nearly half (49%; 86/177) were on a biologic, and most (89% 157/177) were on conventional DMARDS, Most patients were in CDAI remission (32%) or low disease activity (LDA: 38%).

Patient Reported Outcomes

PROMIS and legacy scale scores are shown in Table 2. Mean patient global and pain scores were approximately 30 on a 100-point scale, and fatigue was 40. All legacy PROs were positively skewed. Floor effects were evident with the pain, fatigue and patient global VASs; 26 (15%) reported no pain, 18 (10%) reported no fatigue, and 31 (18%) scored 0 on the Patient Global (very well). MHAQ scores reflected minimal disability with 81 people (46%) scoring 0. PROMIS scores were distributed across a broad range (i.e., -2.7 to +3.1 SD; see Fig 1) for each PROMIS measure, and were relatively normally distributed except Pain Intensity, Pain Interference and Depression which showed positive skewing. Across PROMIS instruments, mean scores were between 45 and 55 (i.e., within normal limits or 0.5 SD of US general population norms) except for Physical Function and Pain Intensity which were significantly lower than population norms. Across CATs, the median number of items administered was 3, except for Anger which was 4, and median completion time was 7 minutes.

Reliability. Among the 34 participants who completed PROMIS measures 2.2 (0.6) days later, correlations ranged from .725 (Sleep-related Impairment) to .975 (Physical Function), with 7 scales ≥ .822 (Table 2). Cronbach’s alpha showed high internal consistency ranging from .906 (Pain Intensity 3a) to .988 (Fatigue).
Correlations among PROMIS Measures. Correlations among individual PROMIS scales ranged from weak to strong (e.g., r’s 0.23 to 0.85; all p’s ≤ .002) (Table 3). The highest correlations (≥ 0.7) were evident among scales measuring similar constructs: physical health (e.g., pain, fatigue, sleep), mental health (e.g., depression, anxiety, anger), and social health (Ability to Participate in Social Roles and Satisfaction with Social Roles and Activities). Physical Function was also strongly correlated with Pain Interference (r = -0.71) and Ability to Participate in Social Roles (r = 0.70). The two participation scales were moderately to strongly (r’s -.34 to .70) correlated with all symptom and function scales.

Convergent and Known Groups Validation with Legacy Instruments. The PROMIS Physical Function, Pain Intensity and Pain Interference and Fatigue instruments correlated strongly (rho’s ≥ 0.75; p’s ≤ .01) with corresponding legacy instruments (Table 4). Patient Global was moderately to strongly (rho’s ≥ 0.68; p’s ≤ .01) associated with PROMIS scales.

Table 1. Participant characteristics (N = 177).

| Characteristic                               | N   | Value         |
|---------------------------------------------|-----|---------------|
| Age (Mean SD; years)                        | 177 | 55.5 ± 13.3   |
| Female sex                                  | 177 | 145 (82%)     |
| Race                                        | 177 |               |
| White                                       |     | 146 (83%)     |
| Black                                       |     | 22 (12%)      |
| Other                                       |     | 9 (5%)        |
| Education                                   | 175 |               |
| High School                                 |     | 42 (24%)      |
| College                                     |     | 133 (76%)     |
| Employment Status                           | 176 |               |
| Full or Part Time                           |     | 99 (56%)      |
| Not working                                 |     | 19 (11%)      |
| Disabled                                    |     | 39 (22%)      |
| Disabled-not RA                             |     | 19 (11%)      |
| RA Disease Duration                         | 177 |               |
| Mean SD (years)                             |     | 11.6 ± 9.5    |
| < 2 years                                   |     | 23 (13%)      |
| CDAI (mean; SD)*                            | 176 | 7.9 ± 7.8     |
| Remission                                   |     | 56 (32%)      |
| Low disease activity                        |     | 67 (38%)      |
| Moderate disease activity                   |     | 39 (22%)      |
| High disease activity                       |     | 14 (8%)       |
| Tender Joint Count (28)                     | 176 | 1.4 ± 2.9     |
| Swollen Joint Count (28)                    | 175 | 2.3 ± 3.4     |
| MD Global Assessment (100 mm VAS)           | 175 | 13.9 ± 15.3   |
| Morning Stiffness                           |     | 124 (71%)     |
| Yes                                         |     | 124 (71%)     |
| Mean duration (min)                         |     | 62 ± 87       |
| MHAQ* (mean; SD)                            | 175 | 0.3 ± 0.4     |
| Pain (100 mm VAS)                           | 175 | 31 ± 28       |
| Patient Global Assessment (100 mm VAS)      | 176 | 29 ± 27       |
| Fatigue (100 mm VAS)                        | 175 | 40 ± 31       |

*Modified Health Assessment Scale

doi:10.1371/journal.pone.0138543.t001
The lowest associations were between Patient Global and PROMIS mood scales (Anger, \( \rho = 0.32 \); Depression, \( \rho = 0.41 \), and Anxiety, \( \rho = 0.41 \); all \( p' < 0.01 \)).

In general, PROMIS scores worsened significantly (\( p < 0.05 \)) as disease activity increased from remission through high disease activity (Table 5); physical health scores worsened by 12–17 points, social domains by 16–18 points, and emotional health by 8–11 points. A dose-response relationship was evident in Physical Function. Similar trends were evident in all scales, although scores were not significantly different between low and moderate disease activity levels for most measures, except Anger, which remained within normal limits for remission, low, and moderate disease activity and worsened only in those with high disease activity. In all PROMIS physical and social health instruments, increases in impairment were highest between people in LDA vs. remission (\( \geq 0.7 \) SD); Anxiety and Depression worsened by nearly 0.5 SD, while Anger increased only slightly. Similar patterns were seen between those in high vs. moderate disease activity, where impairment increased on average 0.5 SD; the exception was Pain Intensity, where scores increased an average of 3.4 points.

**Discussion**

This study is the first to report evidence of the reliability and construct validity of 11 PROMIS instruments in people with RA within the context of ongoing care. We selected PROMIS instruments that reflect outcomes people with RA identified as important to them in our foundational work that included a literature review, focus groups with patients, surveys of experts, and combined patient-provider consensus Delphi exercises [15, 16, 32]. The 11 instruments were completed in <11 minutes by 75% of patients. Pain (Intensity and Interference), Physical Function and Fatigue scores correlated highly (rho’s \( \geq 0.75 \)) with corresponding legacy
Fig 1. Distribution of PROMIS and legacy scores in rheumatoid arthritis sample (N = 177).

doi:10.1371/journal.pone.0138543.g001
A dose-response relationship was evident across disease activity levels for the Physical Function, Pain and Fatigue scales. Additional domains we examined including mood, sleep, and participation also showed similar trends. These findings contribute new evidence supporting the feasibility and construct validity of PROMIS when comparing RA with other diseases, as outcomes in comparative effectiveness trials, and for RA clinical care.

Table 3. Correlations among PROMIS scales.

| Physical Function | Pain Intensity | Pain Interference | Fatigue | Sleep Disturb | Sleep Impair | Depress | Anxiety | Anger | Ability to Participate Social | Satisfaction with Role Activities |
|-------------------|---------------|------------------|---------|---------------|-------------|---------|---------|------|-------------------------------|----------------------------------|
| Physical Function | -.561         | - .709           | -.635   | -.376         | -.432       | -.398   | -.361   | -.229| .698                          | .627                             |
| Pain Intensity    | -.561         | - .854           | -.647   | -.493         | -.533       | -.421   | -.437   | -.324| -.509                         | -.544                            |
| Pain Interference | -.709         | - .854           | -.672   | -.480         | -.547       | -.521   | -.515   | -.394| -.640                         | -.618                            |
| Fatigue           | -.635         | - .647           | -.672   | -.453         | -.670       | -.487   | -.523   | -.407| -.607                         | -.581                            |
| Sleep Disturb     | -.376         | - .493           | -.480   | -.453         | -.719       | -.394   | -.401   | -.296| -.341                         | -.389                            |
| Sleep Impairment  | -.432         | - .533           | -.547   | -.670         | -.719       | -.573   | -.616   | -.507| -.461                         | -.434                            |
| Depression        | -.398         | - .421           | -.521   | -.487         | -.394       | -.573   | -.802   | -.761| -.541                         | -.517                            |
| Anxiety           | -.361         | - .437           | -.515   | -.523         | -.401       | -.616   | -.802   | -.737| -.524                         | -.463                            |
| Anger             | -.229         | - .324           | -.394   | -.407         | -.296       | -.507   | -.761   | -.737| -.431                         | -.341                            |
| Ability to        | .698          | - .509           | -.640   | -.607         | -.341       | -.461   | -.541   | -.524| -.431                         | —                                |
| Participate Social| .627          | - .544           | -.618   | -.581         | -.389       | -.434   | -.517   | -.463| -.341                         | .744                             |
| Satisfaction      |               |                  |         |               |             |         |         |      |                               |                                  |
| Roles Activities  |               |                  |         |               |             |         |         |      |                               |                                  |
| CDAI              | -.593         | .537             | .540    | .537          | .312        | .352    | .311    | .280 | -.495                         | -.502                            |

All Pearson correlation coefficients were statistically significant (p ≤ .01). All PROMIS measures are computerized adapted tests, except the Pain Intensity 3a which is a short form.

doi:10.1371/journal.pone.0138543.t003

Table 4. Correlations between PROMIS and legacy measures in RA.

| MHAQ | PROMIS Physical Function | Pain VAS | PROMIS Pain Intensity | PROMIS Pain Interference | Fatigue VAS | PROMIS Fatigue | Patient Global VAS |
|------|--------------------------|----------|-----------------------|--------------------------|-------------|----------------|-------------------|
| MHAQ | 1.000                    | -.752    | .514                  | .541                     | .655        | .493           | .506              | .593              |
| PROMIS Physical Function | -.752 | 1.000 | -.593 | -.601 | -.749 | -.570 | -.645 | -.688 |
| Pain VAS | .514 | -.593 | 1.000 | .856 | .823 | .704 | .642 | .842 |
| PROMIS Pain Intensity | .541 | -.601 | .856 | 1.000 | .842 | .651 | .665 | .759 |
| PROMIS Pain Interference | .655 | -.749 | .823 | .842 | 1.000 | .654 | .690 | .770 |
| Fatigue VAS | .493 | -.570 | .704 | .651 | .654 | 1.000 | .862 | .739 |
| PROMIS Fatigue | .506 | -.645 | .642 | .665 | .690 | .862 | 1.000 | .682 |
| Patient Global VAS | .593 | -.688 | .842 | .759 | .770 | .739 | .682 | 1.000 |

All Pearson correlation coefficients were statistically significant at p < 0.01.

All PROMIS measures are computerized adapted tests, except the Pain Intensity 3a which is a short form.

doi:10.1371/journal.pone.0138543.t004
The process for developing and validating PROs has evolved considerably over the last two decades and now includes recommendations to identify patient-relevant symptoms through qualitative inquiry, cognitively test and debrief of potential items, rigorously psychometrically evaluate, and validate in the targeted patient population and context of intended use (e.g. RCT vs. clinical practice) [3, 23, 33]. PROMIS instruments were initially developed to help researchers obtain precise estimates of symptoms and functional impacts from patients across chronic diseases using a common metric. Although PROMIS was developed and tested in the general US population and later in selected clinical conditions, evaluating the content validity of instruments, construct validity against legacy instruments, and the responsiveness of these instruments in specific conditions is necessary as outlined in the PROMIS instrument maturity model [23].

An important strength of the PROMIS instruments was the ability to capture the experiences using a common T-score metric and across the broad continuum of symptoms and function experienced by people with RA spanning roughly ± 3 SD (or 99.7% of data in a normal distribution). Notably, fatigue, emotional distress, sleep, and participation, which are not currently part of the recommended RA core set [30], also showed a wide distribution of scores, with many individuals reporting significant impairments. Floor and ceiling effects, recognized limitations of many instruments [24, 25], were evident for many patients with legacy measures; for example, in our sample nearly 1 in 2 (46%) scored 0 on the MHAQ. Among the 56 people

Table 5. PROMIS and legacy scores by CDAI disease activity levels.

| Physical Function          | Remission (n = 56) | Low (n = 67)* | Moderate (n = 39)† | High (n = 14) |
|----------------------------|------------------|--------------|-------------------|--------------|
| PROMIS Physical Function   | 50.1a 8.8        | 42.2b 7.1    | 39.2c 5.9         | 32.9d 5.5    |
| MHAQ                       | .1a .3           | .3           | .5c .4            | .8d .5       |
| Pain                       |                  |              |                   |              |
| PROMIS Pain Intensity      | 37.6a 6.6        | 46.4b 6.4    | 48.8bc 6.4        | 52.1c 7.8    |
| PROMIS Pain Interfere      | 45.6a 7.2        | 56.0b 8.3    | 57.8b 6.1         | 63.4c 8.6    |
| Patient Pain VAS           | 5.8a 7.6         | 35.5b 26.2   | 49.9c 25.3        | 55.3c 25.6   |
| Fatigue                    |                  |              |                   |              |
| PROMIS Fatigue CAT         | 46.2a 8.6        | 55.7b 8.3    | 58.5b 6.9         | 64.0c 9.6    |
| Fatigue VAS                | 14.1a 19.2       | 46.3b 28.7   | 55.0bc 28.0       | 66.6c 20.6   |
| Additional Domains         |                  |              |                   |              |
| PROMIS Depression          | 45.7a 7.9        | 50.1b 8.5    | 50.1b 8.8         | 56.2c 8.2    |
| PROMIS Anxiety             | 47.6a 7.3        | 52.2b 8.5    | 51.3b 7.0         | 57.0c 7.8    |
| PROMIS Anger               | 45.3a 7.9        | 47.4a 9.6    | 48.0ab 9.4        | 52.9b 8.8    |
| PROMIS Sleep Disturbance   | 46.6a 8.6        | 53.4bc 8.9   | 52.9b 10.7        | 58.7c 7.9    |
| PROMIS Sleep Impairment    | 46.4a 8.6        | 53.7b 9.6    | 52.9b 8.1         | 59.4c 6.6    |
| PROMIS Ability to Participate Social | 55.8a 8.3 | 49.1b 7.8 | 47.8b 6.8 | 38.8b 6.8 |
| PROMIS Satisfaction with Role Activities | 55.8a 8.7 | 47.8b 9.8 | 45.4a 6.8 | 37.1c 7.3 |
| Patient Global VAS         | 5.3a 6.7         | 29.3b 22.7   | 52.0c 21.0        | 61.1c 25.2   |

Note: Values in the same row not sharing the same subscript are significantly different at p < .05. SD = Standard deviation. All PROMIS measures are computerized adapted tests, except the Pain Intensity 3a which is a short form.

*N = 66 for MHAQ, Pain VAS and Fatigue VAS;
†N = 38 for Depression, Anxiety, Anger, and Ability to Participate Social scales.
in remission, substantial proportions of individuals scored 0 on legacy instruments of pain (41%), physical function (75%), fatigue (27%) and patient global (46%). In contrast, PROMIS scores for people in remission showed considerable dispersion; the range for Pain intensity was 22 points (T-scores of 31 to 52), 43 points for Physical Function (27 to 70) and Satisfaction with Role Activities (24 to 67), and 44 points (22 to 66) for Ability to Participate in Social Roles and Activities. In physical and social domains, the largest increase in impairment was between people in remission and those in LDA. Conversely, in emotional domains, minimal differences were seen among lower levels of disease activity (remission to low, low to moderate), with the greatest differences evident between moderate and high disease activity. Most scores on PROMIS measures were higher in people with moderate vs. low disease activity, though differences were not statistically significant. However, the relatively small number of patients in each group and significantly clustering of individuals around the cut point between low and moderate disease activity may have contributed to this finding.

Reliable, precise, and accurate measurement of symptoms and functional impacts across the continuum of disease activity has never been more important to optimize RA treatment given that remission or LDA is the current target for management.[11, 34]. With the development of biologics and the focus on early, intensive treatment, many people with RA now reach states of remission or LDA; in our sample, 69% were at these targets. Composite RA disease activity measures, (e.g. Disease Activity Score [DAS28], CDAI, Simplified Disease Activity Index [SDAI]) rely on the answer to a single global question about disease activity or health status. However, multidimensional measures such as the SF-36 are proprietary and burdensome to complete and score in clinical practice settings. From the battery of instruments available, we were able to select PROMIS instruments to focus on important outcomes that either can only come from patients (i.e., symptoms) or those that are most practical to obtain by asking patients (impacts). PROMIS CATs offer optimal precision on a common metric with immediate scoring for real time use in clinical encounters. The ability of PROMIS to detect small changes even at the low end of symptoms and disability in patients with minimal disease activity can offer new insight into the relative burden of living with RA and new opportunities to compare the impact and side effects associated with current treatments, as well as the ability to capture changes in HRQL that may be relevant to tapering therapies after achieving a target of remission.

Findings from domains in which we assessed both symptom intensity and impact (e.g., Pain, Sleep, and Participation) produced some discrepancies that were not expected. Median Pain Interference scores were 10 points higher than Pain Intensity, suggesting the impact of pain on day-to-day function may be much greater than what scores on Pain Intensity scores reflect. Among patients in remission (CDAI < 2.8), 36 (64%) had CDAI scores ≤ 1.0, supporting the absence of detectable disease and “deep” remission. Within this group, median T-scores were better than population norms for Pain Intensity (30.7), Pain Interference (39.1), Sleep Impairment (44.5), Depression (43.6), Anger (44.1), Ability to Participate Social (59.1) and Satisfaction with Social Roles and Participation (58.3); Physical Function was at the population norm (50.7). Higher scores may indicate a response shift reflecting how patients adapt to and report their level of symptoms and function over time [35]. Response shifts occur as patients reconceptualize their life circumstances, reprioritize what is important, and recalibrate (e.g., what pain scores of 10 represent) as they learn to live with RA [36]. For instance, some RA patients have reported that when they record a score of “0” on a questionnaire, this does not necessarily represent the absence of a symptom, but instead reflects a new baseline of “what is normal for me” [37]. Thus, our findings also raise important questions in defining the expected “norms” for RA symptoms and function. Further evaluation in larger numbers of patients...
across the continuums of age, disease activity, duration, disability, and adaptation is warranted to define RA norms.

Before widespread use of PROMIS in RA research and care can be recommended, it will be important to evaluate their performance in relevant subgroups and demonstrate that the instruments are sufficiently responsive or sensitive to change over time. Evaluation of how PROMIS scores change with fluctuations in disease activity is needed to define minimally detectable differences and clinically meaningful changes, essential parameters to facilitating their use in longitudinal care for individuals. Whether the PROMIS instruments perform similarly in other forms of arthritis, autoimmune, and inflammatory diseases remains to be determined.

Strengths of this study include use of a well-characterized cohort with the broad range of characteristics reflective of patients seen in real world settings. We evaluated the performance of PROMIS instruments within the context of usual care. Limitations of the study include use of a mostly white, well-educated sample with established RA that was generally well controlled. In our study, participants were English-speaking; there are ongoing efforts to evaluate translated versions of PROMIS instruments and examine cross-cultural validity [38]. The legacy measures used in this study were limited to ACR core set PROs that we routinely administer; PROMIS anxiety, depression and anger measures already have strong evidence of validity with cross-walks available for legacy measures [39–41]. We used PROMIS CATs which require an internet connection to Assessment Center and may not be feasible in some settings. The use of SFs in RA clinical care warrants further study to determine whether these retain sufficient precision for clinical decision-making [42].

Conclusions
This study contributes new evidence supporting the reliability and construct validity of 11 PROMIS instruments in RA and feasibility of real-time administration and scoring for use in clinical practice. Results demonstrate the considerable impact that RA may have on multiple domains of physical, emotional, and social health. This work provides important preliminary data supporting the applicability of PROMIS in RA research and care with broad implications for other forms of inflammatory and autoimmune diseases in estimating the intensity and impact of symptoms and function important to patients. Ongoing validation of the ‘universal’ PROMIS instruments in specific diseases such as RA can facilitate comparisons across diseases, treatments, cultures, and countries.

Acknowledgments
We wish to thank the following individuals for their assistance: patient participants; Johns Hopkins Arthritis Center rheumatologists (Thomas Grader-Beck, Uzma Haque, Grant Louie, Kristi Mizelle, Rebecca Manno) and fellows; Michelle Jones, Brandy Miles, and other members of the clinic and research staff; Richard Gershon, Monica Prudencio, and the PROMIS Assessment Center at Northwestern University; members of our PCORI Pilot Project external stakeholder advisory group (Laure Gossec, Sarah Hewlett, Amye Leong, April Naegeli, Ben Nelson, Enkeleida Nikai, Marcy O’Koon, Kenneth Saag, Patience White, James Witter, and Kelly Young) for their helpful guidance and comments throughout the study. **Disclaimers:** All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors or Methodology Committee, or the official views of NIAMS or the National Institutes of Health.
Author Contributions
Conceived and designed the experiments: SJB AMO KCS COB. Performed the experiments: SJB AMO TD ED VR KCS COB. Analyzed the data: SJB AMO KCS COB. Wrote the paper: SJB AMO TD ED VR KCS COB.

References
1. Selby JV, Beal AC, Frank L. The Patient-Centered Outcomes Research Institute (PCORI) national priorities for research and initial research agenda. JAMA. 2012; 307(15):1583–4. doi: 307/15/1583 [pii]; doi: 10.1001/jama.2012.500 PMID: 22511682.
2. Santana MJ, Haverman L, Absolom K, Takeuchi E, Feeny D, Grootenhuis M, et al. Training clinicians in how to use patient-reported outcome measures in routine clinical practice. Qual Life Res. 2015. doi:10.1007/s11136-014-0903-5 PMID: 25589231.
3. Food and Drug Administration. Guidance for industry on patient-reported outcome measures: Use in medical product development to support labeling claims. Federal Register. 2009; 74(235):65132–3.
4. Centers for Disease Control and Prevention. Prevalence and most common causes of disability among adults—United States, 2005. MMWR Morbidity and mortality weekly report. 2009; 58(16):421–6. PMID: 19407734.
5. Hootman JM, Helmick CG. Projections of US prevalence of arthritis and associated activity limitations. Arthritis and rheumatism. 2006; 54(1):226–9. doi: 10.1002/art.21562 PMID: 16385518.
6. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis and rheumatism. 2008; 58(1):26–35. doi: 10.1002/art.23176 PMID: 18163497; PubMed Central PMCID: PMC3266664.
7. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis and rheumatism. 2008; 58(1):15–25. doi: 10.1002/art.23177 PMID: 18163481.
8. Sanderson T, Morris M, Calnan M, Richards P, Hewlett S. What outcomes from pharmacologic treatments are important to people with rheumatoid arthritis? Creating the basis of a patient core set. Arthritis Care Res (Hoboken). 2010; 62(5):640–6. Epub 2010/05/13. doi:10.1002/acr.20034 PMID: 20461785; PubMed Central PMCID: PMC2887082.
9. Sanderson T, Kirwan J. Patient-reported outcomes for arthritis: time to focus on personal life impact measures? Arthritis and rheumatism. 2009; 61(1):1–3. Epub 2009/01/01. doi:10.1002/art.24270 PMID: 19116964.
10. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993; 36(6):729–40. PMID: 8507213.
11. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis. Arthritis Care & Research. 2012; 64(5):625–39. doi: 10.1002acr.21641
12. Kirwan JR, Minnock P, Adejado A, Bresnihan B, Choy E, de Wit M, et al. Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. Journal of Rheumatology. 2007; 34(5):1174–7. PMID: 17477482.
13. Hewlett S, Cockshott Z, Byron M, Kitchen K, Tipler S, Pope D, et al. Patients’ perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthritis & Rheumatism. 2005; 53(5):697–702.
14. Sanderson T, Morris M, Calnan M, Richards P, Hewlett S. What outcomes from pharmacologic treatments are important to people with rheumatoid arthritis? Creating the basis of a patient core set. Arthritis Care & Research. 2010; 62(5):640–6.
15. Bartlett SJ, Hewlett S, Bingham CO 3rd, Woodworth TG, Alten R, Pohl C, et al. Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. Ann Rheum Dis. 2012; 71(11):1855–60. doi: 10.1136/annrheumdis-2011-201201 PMID: 22772326.
16. Gossec L, Dougados M, Rinecheval N, Balanescu A, Bourpas DT, Canadello S, et al. Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Ann Rheum Dis. 2009; 68(11):1690–5. doi:10.1136/ard.2008.100271 PMID: 19054825.
17. Berthelot JM, De BM, Morel J, Benatig F, Constantin A, Gaudin P, et al. A tool to identify recent or present rheumatoid arthritis flare from both patient and physician perspectives: The ‘FLARE’ instrument.
18. Bingham CO III, Alten R, Bartlett SJ, Bykerk VP, Brooks PM, Choy E, et al. Identifying preliminary domains to detect and measure rheumatoid arthritis flares: report of the OMERACT 10 RA Flare Working Group. J Rheumatol. 2011; 38(8):1751–8. doi: 10.3899/jrheum.110401 PMID: 21807797.

19. Alten R, Pohl C, Choy EH, Christensen R, Furst DE, Hewlett SE, et al. Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working Group. J Rheumatol. 2011; 38(8):1745–50. doi: 10.3899/jrheum.110400 PMID: 21807796.

20. Bingham CO III, Alten R, de Wit MP. The importance of patient participation in measuring rheumatoid arthritis flares. Ann Rheum Dis. 2012; 71(7):1107–9. doi: annrheumdis-2011-200870 [pii]; doi: 10.1136/annrheumdis-2011-200870 PMID: 22323439.

21. Methodology Committee of the Patient-Centered Outcomes Research Institute. Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective. JAMA. 2012; 307(15):1636–40. doi: 10.1001/jama.2012.466 PMID: 22511692.

22. Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity—establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2—assessing respondent understanding. Value Health. 2011; 14(8):978–88. doi: 10.1016/j.jval.2011.06.013 PMID: 22152166.

23. PROMIS instrument development and psychometric evaluation scientific standards 2014.

24. Fries JF, Cella D, Rose M, Krishnan E, Bruce B. Progress in assessing physical function in arthritis: PROMIS short forms and computerized adaptive testing. Journal of Rheumatology. 2009; 36(9):2061–6. doi: 10.3899/jrheum.090358 PMID: 19738214.

25. Fries JF, Krishnan E, Rose M, Lingala B, Bruce B. Improved responsiveness and reduced sample size requirements of PROMIS physical function scales with item response theory. Arthritis Research & Therapy. 2011; 13(5):R147. doi: ar3461 [pii]; doi: 10.1186/ar3461.

26. Fries JF, Bruce B, Cella D. The promise of PROMIS: using item response theory to improve assessment of patient-reported outcomes. Clin Exp Rheumatol. 2005; 23(S Suppl 39):S53–S7.

27. Bykerk VP, Bingham CO III, Choy EH, Boire G, Harraoui B, Lin D, et al. The OMERACT Preliminary Flare Questionnaire (PFQ) is responsive to change and able to detect clinically important worsening indicating need for treatment change in the Canadian early arthritis cohort. EULAR 2012.4014.

28. Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. J Clin Epidemiol. 2010; 63(11):1179–94. doi: 10.1016/j.jclinepi.2010.04.011 PMID: 20685078.

29. Cella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve B, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care. 2007; 45(5 Suppl 1):S3–S11. PMID: 17443116.

30. Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis. 2008; 67(10):1360–4. doi: 10.1136/ard.2008.091454 PMID: 18791055.

31. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases. 2010; 69(9):1580–8. doi: 10.1136/ard.2010.138461 PMID: 20699241.

32. Hewlett S, Sanderson T, May J, Alten R, Bingham CO 3rd, Cross M, et al. 'I'm hurting, I want to kill myself': rheumatoid arthritis flare is more than a high joint count—an international patient perspective on flare where medical help is sought. Rheumatology (Oxford). 2012; 51(1):69–76. doi: 10.1093/rheumatology/keq455 PMID: 21565901.

33. Schipper LG, van Hulst LT, Grol R, van Riel PL, Hulscher ME, Fransen J. Meta-analysis of tight control strategies in rheumatoid arthritis: protocalized treatment has additional value with respect to the clinical outcome. Rheumatology (Oxford). 2010; 49(11):2154–64. doi: keq195 [pii]; doi: 10.1093/rheumatology/keq195.

34. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheumatic drugs: 2013 update. Ann Rheum Dis. 2014; 73(3):492–509. doi: 10.1136/annrheumdis-2013-204573 PMID: 24161836; PubMed Central PMCID: PMC3933074.

35. Schwartz CE, Bode R, Repucci N, Becker J, Sprangers MA, Fayers PM. The clinical significance of adaptation to changing health: a meta-analysis of response shift. Qual Life Res. 2006; 15(9):1533–50. doi: 10.1007/s11136-006-0025-9 PMID: 17031503.
36. Sprangers MA, Schwartz CE. Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med. 1999; 48(11):1507–15. PMID: 10400253.

37. Orbai AM, Smith KC, Bartlett SJ, De Leon E, Bingham CO 3rd. "Stiffness has different meanings, I think, to everyone": examining stiffness from the perspective of people living with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014; 66(11):1662–72. doi: 10.1002/acr.22374 PMID: 24891304; PubMed Central PMCID: PMC4211985.

38. Alonso J, Bartlett SJ, Rose M, Aaronson NK, Chaplin JE, Efficace F, et al. The case for an international patient-reported outcomes measurement information system (PROMIS(R)) initiative. Health Qual Life Outcomes. 2013; 11:210. doi: 10.1186/1477-7525-11-210 PMID: 24359143; PubMed Central PMCID: PMC3879205.

39. Pilkonis PA, Choi SW, Reise SP, Stover AM, Riley WT, Cella D. Item banks for measuring emotional distress from the Patient-Reported Outcomes Measurement Information System (PROMIS(R)): depression, anxiety, and anger. Assessment. 2011; 18(3):263–83. Epub 2011/06/24. doi: 10.1177/1073191111411667 PMID: 21697139; PubMed Central PMCID: PMCPMC3153635.

40. Schalet BD, Cook KF, Choi SW, Cella D. Establishing a common metric for self-reported anxiety: linking the MASQ, PANAS, and GAD-7 to PROMIS Anxiety. JAnxietyDisord. 2014; 28(1):88–96. doi: S0887-6185(13)00215-6 [pii]; doi: 10.1016/j.janxdis.2013.11.006

41. Choi SW, Schalet BD, Cook KF, Cella D. Establishing a Common Metric for Depressive Symptoms: Linking the BDI-II, CES-D, and PHQ-9 to PROMIS Depression. Psychoi Assess. 2014.

42. Lai JS, Cella D, Choi S, Junghaenel DU, Christodoulou C, Gershon R, et al. How item banks and their application can influence measurement practice in rehabilitation medicine: a PROMIS fatigue item bank example. ArchPhysMedRehabil. 2011; 92(10 Suppl):S20–S7. doi: S0003-9993(11)00680-0 [pii]; doi: 10.1016/j.apmr.2010.08.033